Search results
Results from the WOW.Com Content Network
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA) or “Grey Scale”, is a rare syndrome characterized by painful skin lesions.The pathogenesis of calciphylaxis is unclear but believed to involve calcification of the small blood vessels located within the fatty tissue and deeper layers of the skin, blood clots, and eventual death of skin cells due to lack of blood flow. [1]
The US National Osteoporosis Foundation recommends pharmacologic treatment for patients with hip or spine fracture thought to be related to osteoporosis, those with BMD 2.5 SD or more below the young normal mean (T-score -2.5 or below), and those with BMD between 1 and 2.5 SD below normal mean whose 10-year risk, using FRAX, for hip fracture is ...
In general, aluminium concentrations in the blood will be less than 10 mcg/L, or fewer than 60 mcg/L in dialysis patients. Toxicity usually occurs at concentrations greater than 100 mcg/L. [ 1 ] Aluminium levels in the blood, bone, urine, and feces can be measured to confirm aluminium load and toxicosis.
Richard Eastell (born 12 February 1953) is a British medical doctor and Professor of Bone Metabolism at the University of Sheffield. [1] He was born in Shipley (West Yorkshire) and attended the Salt Grammar School, [citation needed] later graduating from the University of Edinburgh in 1977 with an MB ChB and in 1984 with an MD [2] and achieved prominence as an expert in osteoporosis.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
Observational data from large registries of dialysis patients suggests that early start of dialysis may be harmful. [19] The most recent published guidelines from Canada, for when to initiate dialysis, recommend an intent to defer dialysis until a patient has definite kidney failure symptoms, which may occur at an estimated GFR of 5–9 ml/min ...
Romosozumab is used for osteoporosis to decrease the risk of fractures. [10] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab.
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...